Clinical Cancer Research, Vol 3, Issue 3 339-345, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs

CB Siegall, D Liggitt, D Chace, B Mixan, J Sugai, T Davidson and M Steinitz
Molecular Immunology Department, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA. Clay_B._Siegall@ccmail.bms.com

Clinical trials of immunotoxins in cancer patients have been limited in many cases by vascular leak syndrome (VLS). Recently, rats were identified as a model for VLS induced by BR96 sFv-PE40, a carcinoma-reactive single-chain immunotoxin. In this study, the toxin component of this immunotoxin, PE40, was found to be responsible for inducing hydrothorax in rats, thereby demonstrating that direct binding to the BR96 antigen was not essential to the onset of VLS. Mutational analysis of PE40 determined that both ADP ribosylation and proteolytic processing functions innate to Pseudomonas exotoxin A (PE) were necessary for PE40 to induce hydrothorax in rats; however, neither function by itself was sufficient for VLS induction. Additionally, nonsteroidal anti-inflammatory agents were found to block VLS in rats receiving BR96 sFv-PE40. These results demonstrate that the toxin component of PE-based immunotoxins induce VLS and suggest agents for clinical management of the toxicity.

This article has been cited by other articles:

				Y. Su, J. Ortiz, S. Liu, T. H. Bugge, R. Singh, S. H. Leppla, and A. E. Frankel Systematic Urokinase-Activated Anthrax Toxin Therapy Produces Regressions of Subcutaneous Human Non-Small Cell Lung Tumor in Athymic Nude Mice Cancer Res., April 1, 2007; 67(7): 3329 - 3336. [Abstract] [Full Text] [PDF]

				C. Di Paolo, J. Willuda, S. Kubetzko, I. Lauffer, D. Tschudi, R. Waibel, A. Pluckthun, R. A. Stahel, and U. Zangemeister-Wittke A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity Clin. Cancer Res., July 1, 2003; 9(7): 2837 - 2848. [Abstract] [Full Text] [PDF]

				J. A. Posey, M. B. Khazaeli, M. A. Bookman, A. Nowrouzi, W. E. Grizzle, J. Thornton, D. E. Carey, J. M. Lorenz, A. P. Sing, C. B. Siegall, et al. A Phase I Trial of the Single-Chain Immunotoxin SGN-10 (BR96 sFv-PE40) in Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3092 - 3099. [Abstract] [Full Text] [PDF]

				M. Onda, M. Willingham, Q.-c. Wang, R. J. Kreitman, Y. Tsutsumi, S. Nagata, and I. Pastan Inhibition of TNF-{alpha} Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2 J. Immunol., December 15, 2000; 165(12): 7150 - 7156. [Abstract] [Full Text] [PDF]

				R. J. Kreitman, W. H. Wilson, J. D. White, M. Stetler-Stevenson, E. S. Jaffe, S. Giardina, T. A. Waldmann, and I. Pastan Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies J. Clin. Oncol., April 1, 2000; 18(8): 1622 - 1636. [Abstract] [Full Text] [PDF]

				H.G. Haggerty, W.A. Warner, C.R. Comereski, W.M. Peden, L.E. Mezza, B.D. Damle, C.B. Siegall, and T.J. Davidson BR96 sFv-PE40 Immunotoxin: Nonclinical Safety Assessment Toxicol Pathol, January 1, 1999; 27(1): 87 - 94. [Abstract] [PDF]